Trial Profile
A retrospective study investigating efficacy of everolimus and sunitinib as first and second line therapy in subjects with metastatic papillary renal cell carcinoma (pRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 Apr 2016 New trial record